Treatment and re-treatment results of HCV patients in the DAA era.

Felix PiechaJan-Michael GänßlerAnn-Kathrin OzgaMalte H WehmeyerJulia DietzJohannes KluweAlena LaschtowitzJohann von FeldenMartina SterneckSabine JordanSven PischkeAnsgar W LohseJulian Schulze Zur Wiesch

Published in: PloS one (2020)

Overall, DAA re-treatments were highly effective in this real-world cohort and only a minority of patients failed more than two treatment courses. Switching to-or addition of-a new drug class seem to be valid options for the re-treatment of patients especially after failure of an interferon-based regimen.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
emergency department
combination therapy
hepatitis c virus
dendritic cells
human immunodeficiency virus